2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Vilobelimab

By sjmartinez • May 23, 2025

Nadig N, Bhimraj A, Cawcutt K, Chiotos K, Dzierba AL, Kim AY, Martin GS, Pearson JC, Shumaker AH, Baden LR, Bedimo R, Cheng VC, Chew KW, Daar ES, Glidden DV, Hardy EJ, Johnson S, Li JZ, MacBrayne C, Nakamura MM, Riley L, Shafer RW, Shoham S, Tebas P, Tien PC, Loveless J, Falck-Ytter Y, Morgan RL, Gandhi RT. 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Vilobelimab. Clin Infect Dis. 2025 May 22:ciaf235. doi: 10.1093/cid/ciaf235. Epub ahead of print. PMID: 40402009.

Tags: covid-19, guideline, Infectious Diseases, monoclonal antibody, Publications, SARS-CoV-2, vilobelimab

High affinity CD16 polymorphism associated with reduced risk of severe COVID-19

Qualls AE, Tsao T, Lui I, Lim SA, Su Y, Chen E, Duchen D, Maecker HT, Kim-Schulze S, Montgomery RR, Krammer F, Langelier CR, Levy[...]

Precision medicine evaluation of heterogeneity of treatment effect for a time-to-event outcome with application in a trial of Initial treatment for people living with HIV

Zheng Y, Currier JS, Hughes MD. Precision medicine evaluation of heterogeneity of treatment effect for a time-to-event outcome with application in a trial of Initial[...]

Comparative Effectiveness of Long-Acting Lipoglycopeptides vs Standard-of-Care Antibiotics in Serious Bacterial Infections

Goodman-Meza D, Weiss RE, Poimboeuf ML, Feng J, Vijayan T, Martinello M, Matthews GV, Dore GJ. Comparative Effectiveness of Long-Acting Lipoglycopeptides vs Standard-of-Care Antibiotics in[...]